
NYSE:BSX
This summary was created by AI, based on 10 opinions in the last 12 months.
Boston Scientific Corp (BSX-N) has been experiencing challenges lately, with a notable decline in stock performance since 2025, breaking critical support levels and exhibiting technical weaknesses as it currently trades below its 200-day moving average. Organic growth has been subpar, as the company recently cut guidance from projected rates, which has contributed to a lack of investor confidence. While the firm is recognized as a leading player in the medical device sector, specifically in non-invasive heart instrumentation, competition has intensified, leading to market share losses against bigger players like Medtronic and Abbott. Despite a strong long-term outlook fueled by aging demographics and increasing demand for cardiovascular procedures, analysts are cautious, recommending a wait-and-see approach as the current valuation appears too high. Overall, Boston Scientific remains a quality organization within its sector, but near-term uncertainties warrant skepticism.
An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.
(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.